Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood-to-plasma ratio

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Blood-to-plasma ratio. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-000302-39 Sponsor Protocol Number: IN-ES-380-4475 Start Date*: 2018-06-18
    Sponsor Name:Fundació Lluita contra la SIDA
    Full Title: Bictegravir concentrations and antiviral activity in cerebrospinal fluid in HIV-1 Infected individuals
    Medical condition: HIV-1 infected individuals
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001961-34 Sponsor Protocol Number: ANRS173 Start Date*: 2019-07-10
    Sponsor Name:INSERM ANRS
    Full Title: ANRS 173 ALTAR A randomized, open-label, phase III trial comparing a dual nucleoside analogues strategy preceded by an induction period with an integrase inhibitor based triple therapy to an immedi...
    Medical condition: Hiv Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003959-11 Sponsor Protocol Number: 1703001 Start Date*: 2020-05-25
    Sponsor Name:Vestre Viken Trust
    Full Title: MUscle Side-Effects of atorvastatin in coronary patients (MUSE) follow-up study
    Medical condition: Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptoms
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000397-19 Sponsor Protocol Number: Ctrl-DM2 Start Date*: 2014-09-09
    Sponsor Name:University Medical Center Groningen
    Full Title: Effects of Combined Treatment of Surgery and Liraglutide on Glycemic Variability and Control in type 2 Diabetes Mellitus: The Ctrl-DM2 Study
    Medical condition: type 2 diabetes with morbid obesity
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003898-26 Sponsor Protocol Number: 516-007 Start Date*: 2019-12-23
    Sponsor Name:Mirati Therapeutics, Inc.
    Full Title: A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO ASSESS THE MASS BALANCE, ROUTE OF ELIMINATION, AND METABOLIC PROFILE OF [14C] LABELED MGCD516 MALATE SALT IN HEALTHY MALE SUBJECTS
    Medical condition: Cancer/oncology
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004209-15 Sponsor Protocol Number: GBT440-007 Start Date*: 2019-01-08
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants with Sickle Cell Disease
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2015-005349-29 Sponsor Protocol Number: CSP.XEL1005 Start Date*: 2016-02-15
    Sponsor Name:Xellia d.o.o.
    Full Title: Plasma levels of crystalline degradation product 1 (CDP-1) in vancomycin- treated patients with normal or impaired renal function
    Medical condition: Not applicable: medical conditions or diseases will not be investigated in this trial. In this trial pharmacokinetic parameters of vancomycin and its degradation products will be determined in bl...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004645-36 Sponsor Protocol Number: TMP-2501-2019-2 Start Date*: 2021-05-31
    Sponsor Name:Fraunhofer Gesellschaft for its Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP)
    Full Title: Impact of different silymarin dosages to decrease drug-induced elevated liver enzymes compared to placebo in a prospective controlled dose finding Phase IIb trial (SILVER)
    Medical condition: Drug-induced elevated liver enzymes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024668 Liver damage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005116-10 Sponsor Protocol Number: ELVIs Start Date*: 2014-04-10
    Sponsor Name:Dr. Daniel Podzamczer Palter (Unidad de VIH. Servicio de Enfermedades Infecciosas. Hospital de Bellvitge).
    Full Title: Elvitegravir concentrations in seminal plasma in HIV-1 infected patients (?ELVIs Study?)
    Medical condition: HIV-1 positive patients
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000379-18 Sponsor Protocol Number: 1.0 Start Date*: 2012-05-04
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: Plasma and synovial fluid pharmacokinetics of cefuroxime and linezolid in patients undergoing elective knee arthroscopy after a single intravenous dose of cefuroxime and linezolid: an exploratory m...
    Medical condition: Subjects under general anaesthesia after a knee surgery get a microdialysis probe insertio into the operated knee and a probe insertion into the thigh on the contralateral side. After the operation...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003495-39 Sponsor Protocol Number: Debio-0932-102 Start Date*: 2012-10-08
    Sponsor Name:Debiopharm SA
    Full Title: A Two-Part, Sequential Design Study to Determine Debio 0932 Absolute Oral Bioavailability, Mass Balance Recovery, Metabolite Profiling and Structural Identification in 3 Cohorts of Healthy Male Sub...
    Medical condition: Debio-0932 is currently under development for the treatment of cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001043-41 Sponsor Protocol Number: 516-005 Start Date*: 2020-11-03
    Sponsor Name:Mirati Therapeutics, Inc.
    Full Title: A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Plat...
    Medical condition: Non-Squamous Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) HU (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001491-35 Sponsor Protocol Number: CB103-C-101 Start Date*: 2017-08-11
    Sponsor Name:Cellestia Biotech AG
    Full Title: A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adu...
    Medical condition: advanced or metastatic solid tumours and haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004677-14 Sponsor Protocol Number: DIABOLO Start Date*: 2018-03-09
    Sponsor Name:Erasmus MC
    Full Title: Dose IndividualizAtion of Beta-lactam and fluOroquinoLone AntiBiotics in ICU patients: to TDM or not to TDM and the effects on Outcome (DIABOLO-study)
    Medical condition: ICU patients with infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001705-24 Sponsor Protocol Number: HE37/12 Start Date*: 2013-02-20
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: Phase II single-arm study of first line treatment with gemcitabine and pazopanib in patients with inoperable locally advanced or metastatic biliary tree cancer (cholangiocarcinoma or gallbladder ca...
    Medical condition: Inoperable locally advanced or metastatic cancer of the biliary tree (cholangiocarcinoma and gallbladder carcinoma)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10017620 Gallbladder carcinoma LLT
    14.1 100000004864 10008593 Cholangiocarcinoma LLT
    14.1 100000004864 10004655 Biliary carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005936-31 Sponsor Protocol Number: SMX18-001 Start Date*: 2021-05-24
    Sponsor Name:Sermonix Pharmaceuticals
    Full Title: An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic E...
    Medical condition: Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004195-19 Sponsor Protocol Number: CREPATS10 Start Date*: 2020-07-07
    Sponsor Name:Centre de Recherche et d’Etudes sur la Pathologie Tropicale et le Sida (CREPATS)
    Full Title: A randomized comparative phase II trial evaluating the capacity of the dual combination doravirine/raltegravir to maintain virological success in HIV-1 infected patients with an HIV-RNA plasma vire...
    Medical condition: HIV disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10020160 HIV disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001867-35 Sponsor Protocol Number: NNCIT-02 Start Date*: 2019-04-24
    Sponsor Name:TikoMed AB
    Full Title: Open, Randomized, Active Comparator-controlled, Multi-Center Study to Evaluate Safety and Efficacy of IBsolvMIR® in Islet Transplantation
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) NO (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001463-21 Sponsor Protocol Number: MK-3682B-037 Start Date*: 2017-08-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the Combination Regimen of MK-3682B (Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic Hepatitis C Virus Genotype 3 Inf...
    Medical condition: Treatment of hepatitis C virus (HCV) infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000074171 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000667-24 Sponsor Protocol Number: ST-920-201 Start Date*: 2019-11-12
    Sponsor Name:Sangamo Therapeutics, Inc.
    Full Title: A Phase I/II, Multicenter, Open-Label, SingleDose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Dise...
    Medical condition: Fabry Disease (X-linked lysosomal storage disease)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 20:15:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA